Amneal Pharmaceuticals Inc (AMRX) Stock Price, Quote & News

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and r...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 908 947 3120

Fax: 908 947 3146

Website: www.amneal.com

Address:

400 Crossing Boulevard, 3rd Floor, Bridgewater, United States

scientificway Aug. 5 at 4:21 AM

$AMRX check out MDXG, huge rev, eps, guidance up. , Chance to get in before explode

0 · Reply

tamperson Aug. 4 at 7:40 PM

$AMRX Analyst sentiment on AMRX is overwhelmingly positive, with consensus ratings ranging from “Buy” to “Strong Buy”. Public.com reports a blend of Strong Buy (29%), Buy (29%), Hold (36%), and a small Strong Sell portion (7%), based on coverage from 14 analysts. MarketBeat and StockAnalysis list AMRX as a Strong Buy with a consensus target of $11.50 (~+46.5% upside). GLTA!

0 · Reply

tamperson Jul. 24 at 9:29 PM

$AMRX Recent News & Analyst Views: • Q2 2025 Earnings Date Confirmed: Amneal is scheduled to report earnings on August 5, 2025, before market open. • Analyst Consensus: MarketBeat shows a “Buy” consensus with an average price target of $11.60, implying ~45% upside. • Bullish Momentum Story: SimplyWall.St models AMRX as 31% undervalued, forecasting 93% annual earnings growth and signaling strong future potential. Current Range: Trading near $8.00, down ~0.9% intraday, with volume (~765K) below its 50 day average (~1.9M). Volume Context: Light volume in recent days suggests a quiet consolidation phase heading into earnings, lacking strong buying or selling pressure.

0 · Reply

tamperson Jul. 21 at 5:04 PM

$AMRX Recent News Highlights 1. Proposed $2.55 B Debt Refinancing: Amneal's subsidiary (Amneal Pharmaceuticals), has launched a major debt restructuring plan. It’s seeking $1.8 billion in seven-year term B loans and issuing $750 million in senior secured notes due 2032. Funds will refinance existing loans, reduce asset-based borrowings, and cover related expenses. This refinancing aims to optimize Amneal’s debt profile, especially by extending maturities and possibly securing better interest terms. 2. Solid Q2 2025 Preliminary Results: Amneal released unaudited preliminary Q2 results through June 30, 2025: Revenue:$720–730 million (+3% YoY) Adjusted EBITD$180–185 million (+13% YoY) Gross leverage reduced from 4.1× to 3.8×; net leverage from 3.9× to 3.7× Pre-tax income rose to $45–56 million vs. $20 million last year. Pipeline wins:FDA approvedBrekiya autoinjector for migraine and cluster headache;strong commercial uptake of CREXONT®; planningBLA submission for Xolair biosimilar in Q4 25.

0 · Reply

tamperson Jul. 21 at 4:45 PM

$AMRX Sector Update: Health Care Stocks Edge Higher Premarket Monday 09:11:43 AM ET, 07/21/2025 - MT Newswires 09:11 AM EDT, 07/21/2025 (MT Newswires) -- Health care stocks were edging higher premarket Monday as the Health Care Select Sector SPDR Fund (XLV) was advancing by 0.2% and the iShares Biotechnology ETF (IBB) was recently up 0.3%. Amneal Pharmaceuticals (AMRX) shares were up more than 3% after the company said it expects to report Q2 income before taxes of $45 million to $56 million, compared with $20 million a year earlier. Evotec (EVO) shares were down nearly 13% after the company lowered its fiscal 2025 revenue guidance to reflect a shift in the revenue mix. Sarepta Therapeutics (SRPT) shares were nearly 10% lower after the company said in a regulatory filing the US Food and Drug Administration has placed a clinical hold on its gene therapy trials for limb-girdle muscular dystrophy.

0 · Reply

NVDAMillionaire Jul. 7 at 10:43 AM

$AMRX Excellent article that nails exactly where AMRX stands right now. So if you want to update your AMRX knowledge or get acquainted with AMRX, this is a must read. https://beyondspx.com/article/amneal-pharmaceuticals-unlocking-value-through-diversification-and-complex-portfolio-expansion-nasdaq-amrx

1 · Reply

DonCorleone77 Jun. 25 at 12:09 PM

$AMRX Amneal Pharmaceuticals announces results from trial evaluating ADL-018 Amneal Pharmaceuticals highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR, developed by Kashiv BioSciences. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compared to XOLAIR in patients with Chronic Idiopathic Urticaria, CIU, or Chronic Spontaneous Urticaria, CSU, who remained symptomatic despite treatment with H1 antihistamines. Omalizumab, a humanized monoclonal antibody that targets free IgE, is indicated for the treatment of severe allergic asthma, chronic rhinosinusitis with nasal polyps, food allergies, and chronic spontaneous urticaria. It is typically administered in a hospital or clinic setting. The clinical study achieved its primary and secondary endpoints by establishing equivalence of therapeutic endpoints and comparable safety between ADL-018 and XOLAIR. Participants received subcutaneous doses of either 150 mg or 300 mg every four weeks for a 24-week period. The primary efficacy measure was the change from baseline in the weekly itch severity score at Week 12 between the treatment arms of ADL-018 and the reference product.

0 · Reply

etruz Jun. 17 at 10:51 AM

$AMRX a 112% EPS q/q a recent FDA approval of a migraine drug (Brekiya) that solves what no competitor presently can .. with brand premium pricing estimated at $334 a pop and still not hitting mass market yet .. Massive upgrade of all facilities to ramp up the generic drug demand healthy 13.43% sales growth .. At this price this stock is screaming BUY !!!!!!

0 · Reply

QuiverQuant Jun. 12 at 1:49 PM

Amneal Pharmaceuticals Receives FDA Approval for Complex Ophthalmic Product, Launch Planned for Q3 2025 Read more on $AMRX: https://www.quiverquant.com/news/Amneal+Pharmaceuticals+Receives+FDA+Approval+for+Complex+Ophthalmic+Product%2C+Launch+Planned+for+Q3+2025

0 · Reply

G101SPM Jun. 12 at 12:16 PM

$AMRX $7.97 bid. DAC $8.20 (8.20.24). CHANGE EXIT TO $12.00 FROM $16.00 in long term on SPM tag notice. BRIEF: Amneal Pharmaceuticals announces U.S FDA approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte. note: Launch of product is planned for the third quarter of 2025.

0 · Reply

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:30 AM EDT - 6 days ago

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Aug 5, 2025, 6:00 AM EDT - 6 days ago

Amneal Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 7:39 AM EDT - 21 days ago

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Jul 21, 2025, 7:38 AM EDT - 21 days ago

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Jul 18, 2025, 7:00 AM EDT - 24 days ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Jul 9, 2025, 8:00 AM EDT - 4 weeks ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jun 25, 2025, 8:00 AM EDT - 6 weeks ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Jun 12, 2025, 8:00 AM EDT - 2 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

May 29, 2025, 4:05 PM EDT - 2 months ago

Amneal to Participate at Upcoming Investor Conferences in June

May 15, 2025, 8:16 AM EDT - 3 months ago

US FDA approves Amneal's migraine treatment

May 15, 2025, 8:00 AM EDT - 3 months ago

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 8, 2025, 7:00 AM EDT - 3 months ago

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 2, 2025, 11:32 AM EDT - 3 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

May 2, 2025, 6:00 AM EDT - 3 months ago

Amneal Reports First Quarter 2025 Financial Results

Apr 11, 2025, 8:00 AM EDT - 4 months ago

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Apr 8, 2025, 4:05 PM EDT - 4 months ago

Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 7, 2025, 8:00 AM EDT - 4 months ago

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Apr 3, 2025, 8:00 AM EDT - 4 months ago

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Mar 19, 2025, 3:14 PM EDT - 5 months ago

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 10, 2025, 4:05 PM EDT - 5 months ago

Amneal to Participate at Upcoming Investor Conference

Mar 3, 2025, 4:05 PM EST - 5 months ago

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Feb 28, 2025, 2:20 PM EST - 5 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:00 AM EST - 5 months ago

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 1:42 PM EST - 6 months ago

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

Feb 19, 2025, 8:00 AM EST - 6 months ago

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

Jan 29, 2025, 8:30 AM EST - 6 months ago

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

Jan 23, 2025, 8:00 AM EST - 7 months ago

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

Dec 4, 2024, 8:00 AM EST - 8 months ago

Amneal to Participate at Upcoming Investor Conferences

Nov 21, 2024, 4:05 PM EST - 9 months ago

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Nov 8, 2024, 3:27 PM EST - 9 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 6:00 AM EST - 9 months ago

Amneal Reports Third Quarter 2024 Financial Results

Oct 21, 2024, 8:00 AM EDT - 10 months ago

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

Oct 8, 2024, 4:05 PM EDT - 10 months ago

Amneal to Report Third Quarter 2024 Results on November 8, 2024

Oct 1, 2024, 6:00 AM EDT - 11 months ago

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

Sep 23, 2024, 8:00 AM EDT - 11 months ago

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration

Aug 20, 2024, 9:45 AM EDT - 1 year ago

Melina Kennedy Joins the LDI, Ltd. Board of Managers

WBTN

Aug 20, 2024, 8:00 AM EDT - 1 year ago

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Aug 9, 2024, 12:14 PM EDT - 1 year ago

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 6:05 AM EDT - 1 year ago

Amneal Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:45 PM EDT - 1 year ago

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson's Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Amneal to Report Second Quarter 2024 Results on August 9, 2024

Jul 10, 2024, 11:40 AM EDT - 1 year ago

Amneal Pharmaceuticals: Maintaining Momentum Is Key To Success

Jul 9, 2024, 4:05 PM EDT - 1 year ago

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Jul 1, 2024, 8:00 AM EDT - 1 year ago

Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Amneal Releases 2023 Environmental, Social and Governance Report

scientificway Aug. 5 at 4:21 AM

$AMRX check out MDXG, huge rev, eps, guidance up. , Chance to get in before explode

0 · Reply

tamperson Aug. 4 at 7:40 PM

0 · Reply

tamperson Jul. 24 at 9:29 PM

0 · Reply

tamperson Jul. 21 at 5:04 PM

0 · Reply

tamperson Jul. 21 at 4:45 PM

0 · Reply

NVDAMillionaire Jul. 7 at 10:43 AM

1 · Reply

DonCorleone77 Jun. 25 at 12:09 PM

0 · Reply

etruz Jun. 17 at 10:51 AM

0 · Reply

QuiverQuant Jun. 12 at 1:49 PM

0 · Reply

G101SPM Jun. 12 at 12:16 PM

0 · Reply

jabroni1111 Jun. 12 at 12:12 PM

$AMRX no reaction to this ?

1 · Reply

tamperson Jun. 7 at 3:15 AM

$AMRX The legs are out for AMRX to run to its next level at 10+. See you all there soon. GLTA!

0 · Reply

StockStratigizer Jun. 6 at 6:46 PM

SUPER RUN INCOMING ON GLMD 🚨 History repeats in small caps… and GLMD fits the mold. 📈 $SIGL — $0.10 to $4+ on float frenzy 📈 $HZNP — $2 to $120+ after biotech breakout 📈 $AQST — $0.70 to $8 on FDA hype 📈 $AMRX — under $1 to $6+ on revival spark 📈 $APTO — $0.30 to $10 on oncology buzz Now GLMD sits quietly… 🔹 Book value: $12 🔹 Cash rich 🔹 Tiny float 🔹 Massive upside potential Same setup. Same coiled spring. All it needs is a spark.

0 · Reply

StocktwitsNews Jun. 4 at 5:24 PM

Amneal Recalls Three Lots Of UTI Drug Over Concerns of Microbial Contamination: Retail Sticks To Bearish Territory $AMRX $VTI $IWM https://stocktwits.com/news/equity/markets/amneal-recalls-three-lots-of-uti-drug/chkumJXRbD3

0 · Reply

tamperson May. 15 at 6:29 PM

$AMRX AMRX should now be catching the attention of the bigger pharmaceuticals based on the market for generic drugs and Trump pushing drug cost reduction for the United States, and to start manufacturing more drugs in America. AMRX is in a great position to grow and be bought out. GLTA!

0 · Reply

mikesterz7 May. 15 at 3:38 PM

$AMRX The company said the injection is the first and only dihydroergotamine (DHE) autoinjector for treating migraine and cluster headaches.

0 · Reply

DonCorleone77 May. 2 at 11:14 AM

$AMRX Amneal Pharmaceuticals backs FY25 adjusted EPS view 65c-70c, consensus 68c Backs FY25 revenue view $3B-$3.1B, consensus $3.03B. Backs FY25 adjusted EBITDA view $650M-$675M.

0 · Reply

DonCorleone77 May. 2 at 11:12 AM

$AMRX Amneal Pharmaceuticals reports Q1 adjusted EPS 21c, consensus 15c Reports Q1 revenue $695M, consensus $715.49M. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT(R) for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to patients, caregivers and customers. As a leading U.S.-based biopharmaceutical company, Amneal is proud to provide millions of Americans with access to affordable and innovative treatments-and we believe we are just getting started. With our diverse portfolio, expansive footprint in the U.S. and globally, and a resilient management team, we are confident in our ability to deliver sustainable growth and value creation for our stakeholders in 2025 and beyond as we embark on our exciting next chapter of growth and success," said Chirag and Chintu Patel, Co-Chief Executive Officers.

0 · Reply

G101SPM Apr. 1 at 12:32 PM

$AMRX $8.38 last. DAC $8.20 (8.20.24). EXIT $16.00. UPDATE: Amneal Pharmaceuticals announces the U.S. launch of BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or intravenous administration note: This new ready-to-use oncology product reduces the compounding preparation steps typically required with administration. First ready-to-use, subcutaneous formulation of Bortezomib now available. Marks Amneal's fourth 505(b)(2) injectable product launch in the last year.

0 · Reply

Thestocktraderhubzee Apr. 1 at 12:11 PM

$AMRX Amneal Pharmaceuticals Unveils BORUZU, First Ready-To-Use Bortezomib Injection For Multiple Myeloma And Mantle Cell Lymphoma

0 · Reply

NVDAMillionaire Mar. 21 at 1:16 PM

$AMRX Digging AMRX's strategic moves in biosimilars and Parkinson's space. Crexent launch looks promising. Watching closely for Q1 performance and potential market share gains. Might start building a position on any dips. solid article: https://beyondspx.com/article/amneal-pharmaceuticals-a-diversified-biopharma-leader-driving-affordability-and-innovation

1 · Reply

W15E Mar. 18 at 3:38 AM

$AMRX 👀🧐

0 · Reply

Market Cap	2.68B
Revenue (ttm)	2.79B
Net Income (ttm)	-116.89M
EPS (ttm)	N/A
PE Ratio	12.25
Forward PE	12.76
Profit Margin	-4.18%
Debt to Equity Ratio	-18.76

Volume	1,727,000
Avg Vol	1,620,232
Day's Range	N/A - N/A
Shares Out	313.42M
Stochastic %K	99%
Beta	1.11
Analysts	Strong Sell
Price Target	$12.00